1. Market Research
  2. > Pharmaceutical Market Trends
  3. > China Large Volume Parenteral (LVP) Industry Report, 2013-2015

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

  • November 2013
  • -
  • Research In China
  • -
  • 65 pages

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the followings:

Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.

Table Of Contents

China Large Volume Parenteral (LVP) Industry Report, 2013-2015
1 Overview of LVP
1.1 Definition and Classification
1.2 Industry Chain

2 Overview of China LVP Industry Development
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution
2. 5 Development Forecast

3 Chinese LVP Market Segments
3.1 Injection for Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.3.1 Fructose Injection
3.3.2 Amino Acid Injection
3.3.3 Fat Emulsion Injection
3.4 Injection for Blood Volume Expansion
3.4.1 Dextran Injection
3.4.2 Hydroxyethyl Starch Injection
3.5 Peritoneal Dialysis Solution

4 Main Companies
4.1 Kelun Pharma
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Clients and Suppliers
4.1.6 R and D and Investment
4.1.7 LVP Business
4.1.8 Development Forecast
4.2 China Resources Double-Crane
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Major Clients
4.2.6 LVP Business
4.2.7 Development Forecast
4.3 Fengyuan Pharmaceutical
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 LVP Business
4.3.7 Development Forecast
4.4 Huaren Pharmaceutical
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R and D and Investment
4.4.7 Development Forecast
4.5 Southwest Pharmaceutical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Clients
4.5.6 LVP Business
4.5.7 Development Forecast
4.6 Lijun International Pharmaceutical (Holding)
4.6.1 Profile
4.6.2 Operation
4.6.3 Shijiazhuang No.4 Pharmaceutical
4.7 Other Companies
4.7.1 Qingzhou Yaowang Medicine
4.7.2 Jilin Dubang Pharmaceutical
4.7.3 Shandong Lukang Cisen Pharmaceutical
4.7.4 China Otsuka Pharmaceutical

5 China LVP Industry Summary and Development Prediction
5.1 Market Size to Ascend but Capacity Growth to Slow Down
5.2 Industry Concentration to Improve and Large Players with obvious Competitive Edges
5.3 Product Structure to Upgrade and New LVP products Development to be Trend

Companies Mentioned

Kelun Pharma
China Resources Double-Crane
Fengyuan Pharmaceutical
Huaren Pharmaceutical
Southwest Pharmaceutical
Lijun International Pharmaceutical (Holding)
Shijiazhuang No.4 Pharmaceutical
Qingzhou Yaowang Medicine
Jilin Dubang Pharmaceutical
Shandong Lukang Cisen Pharmaceutical
China Otsuka Pharmaceutical

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.